Business Wire

ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq:ARQL) today is presenting preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and ...
Business Wire

ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies ...

ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual ...
JSTOR Daily

Reversible Inhibition of Tomato Fruit Gene Expression at High Temperature: Effects on Tomato Fruit Ripening

The reversible inhibition of three ripening-related processes by high-temperature treatment (38°C) was examined in tomato (Lycopersicon esculentum L. cv Daniella) fruit. Ethylene production, color ...
ascopubs.org

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five ...

PURPOSE: To establish the safety and tolerability of ZD1839 (Iressa), a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its pharmacokinetic and ...